Description: Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
Home Page: www.cosmopharma.com
Riverside II
Dublin,
2
Ireland
Phone:
353 1 817 0370
Officers
| Name | Title |
|---|---|
| Mr. Mauro Severino Ajani | Founder & Exec. Chairman |
| Mr. Alessandro E. Della Cha LL.M | CEO & Exec. Director |
| Mr. Ngo Dinh Nhan | Head of R&D - AI & Biomedical IT |
| Mr. Giulio Evangelisti | Head of Production, AI & Biomedical IT |
| Mr. Niall Donnelly | Chief Financial Officer |
| Mr. Marco Lecchi | Chief Operating Officer |
| Mr. Davide Malavasi | Qualified Person & Technical Director |
| Mr. Luigi Longo | Chief Scientific Officer |
| Ms. Hazel Winchester | Head of Investor Relations |
| Mr. Biagio Vigano | Chief People Officer |
Exchange: SW
Country: CH
Currency: Swiss Franc (CHF)
| Forward PE: | 25.5754 |
|---|---|
| Trailing PE: | 28.5446 |
| Price-to-Book MRQ: | 2.2088 |
| Price-to-Sales TTM: | 12.9535 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 292 |